Proteases of the caspase family, especially caspase-1 (ICE)(-like), caspase-3 (CPP32/Yama/apopain)(-like) and caspase-8 (MACH/FLICE/Mch5) proteases, are implicated in Fas (APO-1/CD95)-mediated apoptosis. Here, we show that the caspase-4 (TX/ICH-2/ICE rel II)(-like) protease, another member of the caspase family, is also involved in Fas-mediated apoptosis, based upon the observations: (i) caspase-4 is processed in response to an agonistic anti-Fas antibody treatment, (ii) overexpression of a mutant caspase-4 with active site mutations in both p20 and p10 subunits delays Fas-mediated apoptosis, (iii) microinjected anti-caspase-4 antibodies inhibit Fasmediated apoptosis. Together with our observations that the mutant caspase-4 inhibits the Fas-mediated activation of caspase-3(-like) proteases and puri®ed caspase-4 cleaves pro-caspase-3 to generate a subunit of active form, these results suggest that Fas-mediated apoptosis is driven by a caspase cascade in which the caspase-4(-like) protease transmits a death signal from caspase-8 to caspase-3(-like) proteases probably through directly cleaving pro-caspase-3(-like) proteases.
Introduction
Apoptosis, or programmed cell death, plays an important role in a variety of biological phenomena, including morphogenesis and tissues homeostasis. Genetic studies in the nematode Caenorhabditis elegans have led to the isolation of several genes, including ced-3, ced-4 and ced-9, that are involved in programmed cell death . The expression of ced-3 and ced-4 is required for cell death in dying cells. ced-3 encodes a protein resembling interleukin-1b (IL1b)-converting enzyme (ICE) (Yuan et al., 1993) . Ten members of caspase family proteases have recently been identi®ed , and among them caspase-1 (ICE)(-like), caspase-3 (CPP32/Yama/apopain)(-like) and caspase-2 (ICH-1) proteases are implicated in apoptosis (reviewed in Martin and Green, 1995) . The caspase family proteases have been suggested to constitute a protease cascade (reviewed in Martin and Green, 1995; Enari et al., 1996; Shimizu et al., 1996) .
Fas (also called APO-1/CD95) is a cell surface protein that transmits apoptotic signals (reviewed in Nagata and Golstein, 1995) . It has been reported that Fas-and tumor necrosis factor (TNF) receptor-mediated apoptosis is driven by caspase family, because it is suppressed by their inhibitors, including cowpox virus CrmA Enari et al., 1995; Los et al., 1995) , baculovirus p35 and tetrapeptide caspase-1 and caspase-3 inhibitors (Enari et al., 1995; Los et al., 1995; Schlegel et al., 1996; Chinnaiyan et al., 1996; Hasegawa et al., 1996) . It has also been reported that thymocytes from caspase-1-de®cient mice are resistant to Fas-mediated apoptosis, indicating the direct involvement of caspase-1 itself in this process of thymocyte death (Kuida et al., 1995) . Sequential activation of caspase-1(-like) and caspase-3(-like) proteases has been shown to occur in Fas-mediated apoptosis of mouse lymphoma cell line (Enari et al., 1996) . Recently, a novel caspase family protease, caspase-8 (MACH/FLICE/Mch5),with two FADD-like domains has been described to be involved in transduction of death signals from Fas and TNF receptor directly to other caspase family proteases (Boldin et al., 1996; Muzio et al., 1996; FernandesAlnemri et al., 1996) . Furthermore, it was reported that caspase-8 directly cleaves some of caspases in vitro Muzio et al., 1997) . However, signal transduction pathway in the in vivo caspase cascade is still poorly understood.
In the present study, we have characterized Fasmediated apoptosis in human cell line not expressing the caspase-1, and shown that the caspase-4 (TX/ICH-2/ICE rel II)(-like) protease is involved in the apoptosis.
Results
Caspase-4 and caspase-3 proteins are processed after Fas-stimulation Among of the caspase family, caspase-1(-like), caspase-3(-like) and caspase-2 are implicated in apoptosis, but others remain to be elucidated. In this study, we focused on caspase-4, a caspase family member which is most closely related to caspase-1, and Fas-mediated apoptosis in a human cell line (HeLa) not expressing the caspase-1. To study the possible involvement of caspase-4 in Fasmediated apoptosis, we ®rst examined whether caspase-4 is processed during Fas-mediated apoptosis. Immunoblot analysis with anti-caspase-4 polyclonal antibodies revealed 45 kDa protein corresponding to pro-caspase-4 in NIH3T3 cells which were transiently transfected with the caspase-4 expression plasmid (pCAG-cas4), indicating that the antibodies speci®cally recognize the caspase-4 protein. Pro-caspase-4 was also detected in HepG2, HeLa, and a HeLa derivative, HeLa-FD5 cells (Hasegawa et al., 1996) which express a mutant Fas lacking the C-terminal inhibitory domain (Itoh and Nagata, 1993) (Figure 1a) . To increase the sensitivity to detect processing of pro-caspase-4, we transiently transfected HeLa-FD5 cells with the DNA encoding pro-caspase-4 bearing active site mutations which prevent autoprocessing (Cys258 to Ser and Arg314 to Glu). After treatment with the agonistic anti-Fas antibody which resulted in less than 50% viability of HeLa-FD5 cells within 2 h (not shown), pro-caspase-4 was processed to an intermediate of 35 kDa (p35) (Figure 1b) . When pro-caspase-3 bearing the active site mutations which prevent autoprocessing (Cys163 to Ser and Arg207 to Glu) was transiently overexpressed in HeLa-FD5 cells, it was processed to a 20 kDa intermediate (p20) and also to the active form of caspase-3 following anti-Fas treatment (Figure 1c ), ®ndings consistent with previous observations . Virtually identical results were obtained with HeLa cells (not shown). Thus, pro-caspase-4 and pro-caspase-3 were processed in response to Fasstimulation, suggesting their involvement in Fasmediated apoptosis.
Mutant caspase-4 delays Fas-mediated apoptosis
To investigate the involvement of caspase-4 in the Fasmediated apoptotic pathway, we established stable transfectants of HeLa cells expressing the mutant pro-caspase-4 with active site mutations as described above. The mutant caspase-4 was expected to play as a dominant negative mutant. Five transfectants with dierent levels of mutant pro-caspase-4 expression as assessed by Western blot analysis (Figure 2a) , were analysed for susceptibility to Fas-mediated apoptosis. The clones HeLa-mc4-3, -mc4-7, and -mc4-13, which expressed mutant pro-caspase-4 protein at higher levels, were less susceptible to anit-Fas-mediated apoptosis than the clones HeLa-mc4-4 and -mc4-15, which expressed little or no mutant pro-caspase-4 protein (Figure 2b) , suggesting that the caspase-4 or caspase-4-like protease is involved in the Fas-mediated signaling pathway for cell death.
Microinjected anti-caspase-4 antibodies inhibit Fasmediated apoptosis
To further investigate the involvement of the caspase-4(-like) protease in Fas-mediated apoptosis, we microinjected anti-caspase-4 antibodies into HeLa-FD5 cells. The anti-caspase-4 antibodies speci®cally recognized caspase-4, but not caspase-1 nor caspase-3, although it weakly cross-reacted with caspase-5 ( Figure  3a) . Microinjection of the anti-caspase-4 antibodies, but not control IgG, eectively inhibited Fas-mediated apoptosis ( Figure 3b and Table 1 ). The data, together with the observation that HeLa cells did not express caspase-5 as assessed by Northern blot and RT ± PCR (not shown), further support our conclusion of the involvement of the caspase-4(-like) protease in the Fasmediated apoptotic signaling pathway.
Caspase-4 acts upstream of caspase-3
Since, as described above, the caspase-4(-like) protease was shown to be involved in Fas-mediated apoptosis in HeLa cells in which caspase-3(-like) proteases have been shown to be involved in Fas-mediated apoptosis (Hasegawa et al., 1996) , we determined the molecular ordering of these proteases. As shown in Figure 2c (Figure 2b ) at 6 h, the data indicate that caspase-4 prevents a step leading to the activation of caspase-3(-like) proteases in Fas-mediated apoptosis.
In vitro cleavage of pro-caspase-3 by caspase-4
We next examined the possibility whether caspase-4 directly cleaves pro-caspase-3. Incubation of puri®ed 35 S-methionine-labeled mutant pro-caspase-3 bearing active site mutations with puri®ed recombinant caspase-4 resulted in the cleavage of pro-caspase-3, releasing p12 that corresponds to a subunit of active caspase-3 (Figure 4) . In vitro cleavage of mutant procaspase-3 by caspase-4 was dependent on the concentration of the protease. Puri®ed recombinant caspase-3 also cleaved the 35 S-methionine-labeled mutant procaspase-3 to generate the p17 and p12 which corresponding to subunits of active caspase-3, suggesting autoprocessing activity of caspase-3 (Figure 4 ) in con®rmation of previous observations Xue et al., 1996) . Lysates of bacteria expressing caspase-4 and caspase-3 cleaved pro-caspase-3, but not lysates of bacteria with a control vector (not shown), indicating that the cleavage was not due to contaminating bacterial proteases. Thus, caspase-4 has an ability to process pro-caspase-3 to prop17 and p12 in vitro, suggesting that a death signal is directly transmitted from caspase-4 to caspase-3.
Discussion
We have previously described that caspase-3(-like) proteases are essential for Fas-mediated apoptosis in HeLa and HepG2 cells (Hasegawa et al., 1996) . Here, we have demonstrated that the caspase-4(-like) protease is also involved in Fas-mediated apoptosis in HeLa cells. This conclusion was based upon the following observations: caspase-4 was processed during Fas-mediated apoptosis, and both the expression of a mutant form of caspase-4 and microinjection of the anti-caspase-4 antibodies inhibited Fas-mediated apoptosis.
When mutant pro-caspase-4 was overexpressed, we detected only an intermediate (p35) in processing but not active form of caspase-4. Since, importantly, any active form of caspase-4 was not detected even when apoptosis was induced by overexpression of normal pro-caspase-4 (not shown), the activation of a very small fraction of caspase-4 seems to be sucient for induction of apoptotic events. Furthermore, since the initial activation of pro-caspase-1 occurs by cleavage after Asp at the C-terminus of p20 to make a 35 kDa intermediate and the intermediates of caspase-1 are proteolytically active , the 35 kDa intermediate of caspase-4 may also have some proteolytic activity for auto-activation.
Microinjected antibodies against recombinant caspase-4 might aect not only caspase-4 itself but also other closely related members of the caspase family. However, Figure 3a shows that the antibodies crossreact only weakly with caspase-5, which has 74% identity with caspase-4, but neither with caspase-1 nor caspase-3, which have 53% and 26% identity with caspase-4, respectively. Since we did not detect expressions of caspase-5 in HeLa cells using Northern blot and RT ± PCR (not shown), and anti-caspase-4 antibodies did not detect the 48 kDa band corresponding to pro-caspase-5 protein (Figure 1a) , the inhibition of Fas-mediated apoptosis by microinjection of the anti-caspase-4 antibodies is likely due to the direct inhibitory eects of anti-caspase-4 antibodies on endogenous caspase-4 protein.
Administration of an agonistic anti-Fas antibody to adult mice causes rapid hepatic failure and death (reviewed in Nagata and Golstein, 1995) . Although Fas-mediated apoptosis is impaired in caspase-1-de®cient thymocytes, it is known that Fas-mediated hepatic failure still occurs despite caspase-1 de®cient (Seshadri et al. personal communication). This Microinjection experiments were carried out as described in ®gure 3b. Non-apoptotic cells (intact nuclei) and apoptotic cells ( S-methionine-labeled mutant procaspase-3 protein was incubated with the indicated amounts of puri®ed recombinant caspase-4 or caspase-3 for 3.5 h and the reaction products were analysed by 15% SDS ± PAGE. Cleavage products, p17 and p12, correspond to two subunits of active caspase-3. His-prop17 corresponds to the His-tagged prodomain with the p17 subunit resulting from cleavage at Asp-175. p19 is the amino-terminal cleavage product resulting from cleavage at Asp-9 and indicates that there is no involvement of caspase-1 in Fas-mediated apoptosis of hepatocytes, is consistent with the lack or extremely low levels of caspase-1 mRNA in the liver. Unlike caspase-1, caspase-4 is highly expressed in the liver (not shown; Faucheu et al., 1995; Kamens et al., 1995; Munday et al., 1995) , so caspase-4 might be directly involved in Fas-mediated apoptosis of hepatocytes.
The observation that the expression of mutant procaspase-4 inhibits the Fas-induced activation of caspase-3(-like) proteases which are essential for Fasmediated apoptosis, strongly suggests that caspase-4 acts at a step leading to the activation of caspase-3, and the in vitro cleavage of pro-caspase-3 by caspase-4 raised the possibility that caspase-4 directly processes pro-caspase-3 in vivo. However, since caspase-4 cleaves pro-caspase-3 to release p12 but not p17, both of which are components of active caspase-3 the generation of p17 might be mediated by other members of caspase family. Alternatively, the release of p12 might lead to auto-activation of caspase-3.
How is the caspase-4(-like) protease activated in response to anti-Fas treatment in vivo. Upon activation of Fas and TNF receptor, caspase-8 which contains pro-caspase-1 sequences, binds to Fas/FADD and TNF receptor/TRADD/FADD complex through death eector domain of FADD, and has been suggested to transduce a death signal from Fas and TNF receptor directly to the caspase cascade. Caspase-10 (Mch4) which is structurally similar to caspase-8 has also been isolated . Caspase-10 has been shown to cleave pro-caspase-3 and pro-caspase-7 (Mch3/ICE-LAP3/CMH-1) in vitro , and caspase-8 to cleave several caspase family including pro-caspase-4 in vitro Muzio et al., 1997) . Thus, caspase-8 and/or caspase-10 may be responsible to activate caspase-4(-like) proteases. Fas-initiated death signal(s) might¯ow through multiple pathways of protease cascade, including caspase-8 and/or caspase-10 to caspase-3 and caspase-8 to caspase-4 to caspase-3 in vivo.
Materials and methods

Construction of mutants of caspase-4 and caspase-3 and expression plasmids
The cDNA fragment containing the entire coding region of caspase-4 was inserted into the EcoRI site of the pUC-CAGGS expression vector (Niwa et al., 1991) , generating pCAG-cas4. Site-directed mutagenesis of Cys258 to Ser (C258S) and Arg314 to Glu (R314E) in caspase-4 was performed with uracil-containing single-stranded DNA as the template using Mutan-K (Takara Shuzo Co.). The mutations were introduced by the following oligonucleotides: 5'-GTCCAGGCCTCGAGAGGTGCAAAC for C258S and 5'-CCACACAACGTCAGCTGGGAAGACA-GCACAATG for R314E. The mutations in the ®nal construct were con®rmed by DNA sequencing. The cDNA containing mutations at C258S and R314E was inserted into the EcoRI site of pUC-CAGGS to generate pCAG-cas4 m . To substitute Cys 163 for Ser and Arg207 for Glu in caspase-3, a PCR-based method was used. The ®nal PCR product was cloned into the EcoRI site of pUC-CAGGS to generate pCAG-cas3 m . The same fragments were also cloned into the EcoRI site of pBluescript SK(7) and sequenced.
Antibodies and Western blot analysis
Rabbit polyclonal antibodies against caspase-4 were raised using a GST-caspase-4 fusion protein containing the 114 ± 377th amino acid residue of caspase-4, and were anitypuri®ed. Anti-caspase-3 and anti-Xpress TM monoclonal antibodies were purchased from Transduction Laboratories and Invitrogen, respectively. Western blot analysis was carried out essentially as described elsewhere (Kamada et al., 1995) .
Cell culture and cell death assays
HeLa (clone D98AH2), HeLa-FD5 (Hasegawa et al., 1996) which is a derivative of D98AH2 expressing mutant Fas lacking the C-terminal inhibitory domain (Itoh and Nagata, 1993) , and HepG2 cells were cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS). NIH3T3 cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% FBS. Stable transfectants of HeLa cells expressing mutant pro-caspase-4 with active site mutations in both p20 and p10 subunits were obtained by transfecting cells with pCAG-cas4 m and pRc/ RSV possessing the neomycin resistance marker (Invitrogen) using Lipofectamine (Life Technologies) and selecting with G418 (400 mg/ml). Expression of mutant pro-caspase-4 was con®rmed by Western blot analysis using the anticaspase-4 antibodies. For induction of apoptosis, HeLa, and HeLa-FD5 cells were treated with 1 mg/ml and 0.1 mg/ ml, respectively, of an agonistic anti-Fas antibody (CH-11; Medical and Biological Laboratories, Japan).
Microinjection experiments
HeLa-FD5 cells were seeded on glass coverslips with the medium. The anti-caspase-4 antibodies in phosphate buered saline were microinjected through a glass capillary into the cytoplasm using a Leica microinjection system. Rhodamine isothiocyanate (RITC)-labeled bovine serum albumin (BSA) was coinjected to identify injected cells. After incubation at 378C for 1 h, cells were treated with 1 mg/ml of the agonistic anti-Fas antibody for 1 h, ®xed with 10% formaldehyde solution and stained with Hoechst 33342 for 10 min. Cells were analysed under ā uorescence microscope (Olympus BX-50, Japan) with excitation at 530 nm for RITC and 360 nm for Hoechst 33342.
Preparation of recombinant His 6 -tagged proteases DNA sequences encoding the 120 ± 404th amino acid residue of caspase-1, 105 ± 377th amino acid residue of caspase-4, 122 ± 418th amino acid residue of caspase-5 and 29 ± 277th amino acid residue of caspase-3 were ampli®ed by PCR and subcloned into the E. coli expression vector pRSET A (Invitrogen), in which the protease sequences were placed under the control of the T7 promoter and joined in-frame to sequences encoding an N-terminal fusion peptide, which includes an ATG translation initiation codon and anti-Xpress TM antibody (Invitrogen) recognizable amino acid sequence (Asp-Leu-Tyr-Asp-Asp-Asp-AspLys) and the sequence for six successive histidine residues that function as a metal-binding domain in the translated proteins. The resultant plasmids (pHiscas1, pHiscas4, pHiscas5 and pHiscas3) were transformed into E.coli strain JM109. Induction of recombinant His 6 -tagged proteases was achieved according to the manufacturer's instructions. Cells were harvested and recombinant proteases (caspase-3 and 4) were puri®ed essentially as described elsewhere (Lippke et al., 1996) . Fractions showing proteolytic activity in an in vitro cleavage assay were pooled and dialyzed against buer A (50 mM HEPES, 0.1 M NaCl, 10% (v/v) glycerol, pH 7.5) to remove excess imidazole and were
